Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience

Table 1 Demographic Data of the patients

	Group A(n = 11)	Group B(n = 18)	Group C(n = 7)
Age (mean±SD yr)	46.6 ± 10.6	47.1 ± 7.8	53.6 ± 5.7
Gender (women/men)	4/7	3/15	1/6
Immunosuppression regimen before switch
Tacrolimus＋steroids＋MMF	7	4	1
Tacrolimus＋steroids	4	14	6
Immunosuppression regimen after switch
Sirolimus＋tacrolimus	8	13	5
Sirolimus＋steroids＋tacrolimus	3	5	2

MMF: mycophenolate mofetil.

Table 2 Tumor status at the time of transplantation

	Group A (n = 11)	Group B (n = 18)	Group C (n = 7)
Stage
I	0	0	4
II	0	0	3
III	4	9	0
IV	7	9	0
Grade (WHO)
I	1	0	4
II	6	10	3
III	4	8	0
PVTT
Yes	6	6	0
No	5	12	7

Stage according to pTNM classification[6]; Grade according to WHO definition (grade I: well-differentiated; grade II: moderately-differentiated; grade III, poorly-differentiated); PVTT: portal vein tumor thrombus.